(5-bromo-thiazol-2-yl)-pyridin-3-yl-amine | 923946-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (5-bromo-thiazol-2-yl)-pyridin-3-yl-amine
• 英文别名: 5-bromo-N-(pyridin-3-yl)thiazol-2-amine；5-bromo-N-pyridin-3-yl-1,3-thiazol-2-amine
• CAS: 923946-76-3
• 化学式: C₈H₆BrN₃S
• 分子量: 256.126
• InChiKey: YCEGXEAMIJRCDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-bromo-thiazol-2-yl)-pyridin-3-yl-amine 在 N-羟基-7-氮杂苯并三氮唑 、 sodium methylate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-(4-{3-[2-(Pyridin-3-ylamino)-thiazol-5-ylsulfanyl]-benzoyl}-piperazin-1-yl)-ethanone
  参考文献：
  名称：

  Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors

  摘要：

  A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.060
• 作为产物：
  描述：

  3-吡啶硫脲 在 溴 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 (5-bromo-thiazol-2-yl)-pyridin-3-yl-amine
  参考文献：
  名称：

  Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors

  摘要：

  A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.060

文献信息

• 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Wan Yongqin

  公开号：US20080227783A1

  公开（公告）日：2008-09-18

  The invention provides 5-substituted thiazol-2-yl amino compounds of Formula (I): pharmaceutical compositions comprising such compounds and the use of such compounds for the treatment or prevention of diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Ab 1, Aurora-A, Ber-Ab1, Bmx, CDKI/cyclinB, CHK2, Fes, FGFR3, Flt3, GSK3β, JNK1α1, Lck, MKK4 and TrkB kinases.

  本发明提供了式(I)的5-取代噻唑-2-基氨基化合物，以及包含这种化合物的制药组合物，并将这种化合物用于治疗或预防与异常或失调的激酶活性相关的疾病或障碍，特别是涉及Ab 1、Aurora-A、Ber-Ab1、Bmx、CDKI/cyclinB、CHK2、Fes、FGFR3、Flt3、GSK3β、JNK1α1、Lck、MKK4和TrkB激酶异常激活的疾病或障碍。
• WO2007/16228
  申请人：——

  公开号：——

  公开（公告）日：——
• 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：IRM LLC

  公开号：EP1912959A2

  公开（公告）日：2008-04-23
• [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS EN TANT QU'INHIBITEURS DE KINASE DE PROTÉINE
  申请人：IRM LLC

  公开号：WO2007016228A2

  公开（公告）日：2007-02-08

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Aurora-A, Bcr-Abl, Bmx, CDK1/cyclinB, CHK2, Fes, FGFR3, Flt3, GSK3ß , JNK1a1, Lck, MKK4 and TrkB kinases.
  [FR] La présente invention concerne une nouvelle classe de composés, des compositions pharmaceutiques comprenant de tels composés ainsi que des procédés d'utilisation de tels composés pour traiter les maladies ou les troubles associés à une activité kinase anormale ou dérégulée, en particulier les maladies ou les troubles impliquant une activation anormale des kinases Abl, Aurora-A, Bcr-Abl, Bmx, CDK1/cyclineB, CHK2, Fes, FGFR3, Flt3, GSK3ß, JNK1a1, Lck, MKK4 et TrkB.
• Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors
  作者：Jagabandhu Das、Joseph A. Furch、Chunjian Liu、Robert V. Moquin、James Lin、Steven H. Spergel、Kim W. McIntyre、David J. Shuster、Kathleen D. O’Day、Becky Penhallow、Chen-Yi Hung、Arthur M. Doweyko、Amrita Kamath、Hongjian Zhang、Punit Marathe、Steven B. Kanner、Tai-An Lin、John H. Dodd、Joel C. Barrish、John Wityak

  DOI：10.1016/j.bmcl.2006.04.060

  日期：2006.7

  A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma. (c) 2006 Elsevier Ltd. All rights reserved.